Avanos Medical (NYSE:AVNS) is set to post its quarterly earnings results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.16 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.16. The business had revenue of $180.40 million during the quarter, compared to analyst estimates of $175.15 million. Avanos Medical had a negative net margin of 3.07% and a positive return on equity of 4.09%. The company’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.15 earnings per share. On average, analysts expect Avanos Medical to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
AVNS stock opened at $30.67 on Friday. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of 28.40, a PEG ratio of 4.59 and a beta of 1.19. The firm has a 50-day simple moving average of $30.11 and a two-hundred day simple moving average of $29.40. Avanos Medical has a one year low of $19.46 and a one year high of $48.07. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.96 and a current ratio of 2.77.
In related news, Director Gary Blackford acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was purchased at an average cost of $28.24 per share, with a total value of $282,400.00. Following the transaction, the director now directly owns 29,845 shares of the company’s stock, valued at approximately $842,822.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.51% of the company’s stock.
Several analysts have commented on AVNS shares. Barclays raised shares of Avanos Medical from an “underweight” rating to an “equal weight” rating and set a $30.00 price target for the company in a research report on Monday, April 13th. KeyCorp decreased their price target on shares of Avanos Medical from $48.00 to $45.00 and set an “overweight” rating for the company in a research report on Monday, April 27th. Finally, Morgan Stanley increased their price target on shares of Avanos Medical from $29.00 to $31.00 and gave the company an “underweight” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. Avanos Medical has a consensus rating of “Hold” and a consensus price target of $37.43.
About Avanos Medical
Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.
Read More: Cost of Debt
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.